Top Company News:
Meet the 37-year-old Prodigal JD & Neuroscientist who's making Matrix's thought-downloading brain chip a reality
May 25, 2017 by Javier Hasse of BenZingA
Will Rosellini is a 37-year-old, retired pro baseball player who now holds six graduate degrees, including an M.B.A., master's degrees in neurobiology and neurosciences, and a juris doctor degree.
At 22, Rosellini retired from baseball so he could dedicate his time to studying. Interested in neuroscience, he took all kinds of courses to help him better understand how the brain works and how he could “take metal and push electrons off the metal to disturb the ions next to a nerve.”
Apr 18, 2017 - Company News
Nexeon Medsystems Belgium, SPRL ("Nexeon Belgium" or the "Company") announced today that it has received certification from DEKRA Certification B.V. that the Company complies with the European requirements of ISO 13485 and EN ISO 13485 for a comprehensive quality management system for the design and manufacture of the company’s implantable neurostimulation system. Company management has described this as a critical milestone on the path to launching its neuromodulation platform, both for its leading indication in deep brain stimulation ("DBS") for Parkinson's disease as well as follow-on products for other neurological diseases.
Mar 30, 2017 - by Niahm Marriot of Drug Target Review
Nexeon MedSystems has licensed a portfolio of patents from Marathon Patent Group. The portfolio of 86 patents originated from Siemens AG, one of the world’s preeminent engineering companies. This portfolio protects innovations in the Internet-of-Things (IoT) space, which can be described as the interconnection via the internet of computing devices embedded in everyday objects, enabling them to send and receive data. This technology can be utilised in a wide variety of medical device applications, most notably in hospitals, nursing facilities, or patients’ homes.
Mar 18, 2016 - by James Cavuoto of NeuroTech Reports
When internet entrepreneur Bryan Johnson launched Kernel last year, he decided on a different approach from other neurotech firms. Rather than target a specific device for a specific disease, the company is more interested in building a broad technology platform that may prove useful in a number of applications down the road.... Johnson may not be the only entrepreneur interested in broadening neurotech’s reach. A recent article in theverge.com reports that Tesla CEO Elon Musk has begun putting together a team to explore the possibilities of human augmentation. And Nexeon MedSystems CEO Will Rosellini is reportedly a proponent of transhumanism, which foresees the day when man and machine meld to form a new species.
Jan 24, 2017 - by Nick Ismail of Information Age
As smart devices connected by the Internet of Things become an increasing presence in homes and on the streets, the next stage is moving this technology to the healthcare system. In 2013, President Obama launched the BRAIN Initiative as a large-scale effort to equip researchers with insights necessary for treating a wide variety of brain disorders like Alzheimer’s, schizophrenia, autism, epilepsy, and traumatic brain injury. The World Health Organization estimates that devastating brain disorders affect more than one billion people worldwide.
Jan 23, 2017 - by Olivia Nguyen of DMagazine
"The Form 10 process has two immediate benefits," said Chairman and CEO Will Rosellini. "One, the financial transparency inherent in being a fully-reporting company will reveal our ongoing commitment to running lean operations and optimizing for our shareholder's return on equity. And secondly... I'm confident that a slow approach to a registered public offering offers a better opportunity for our existing and new shareholders."